ConductScience.org, home

Trial · NCT07879690

Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChange in serum anti-thyroid peroxidase (anti-TPO) antibody levelsBaseline (month 0) and month 12Serum anti-TPO antibodies (IU/mL) measured by immunoassay in a fasting morning blood sample. Change from baseline to month 12 is compared between groups.
SecondaryChange in serum anti-thyroglobulin (anti-Tg) antibody levelsBaseline, month 4, month 8 and month 12Serum anti-Tg antibodies (IU/mL) measured by immunoassay.
SecondaryChange in high-sensitivity C-reactive protein (hs-CRP)Baseline, month 4, month 8 and month 12Serum hs-CRP (mg/L) measured by immunoturbidimetry or nephelometry.
SecondaryChange in erythrocyte sedimentation rate (ESR)Baseline, month 4, month 8 and month 12ESR (mm/h) measured by the Westergren method.
SecondaryChange in fecal zonulinBaseline, month 4, month 8 and month 12Fecal zonulin measured by ELISA in a stool sample, as a marker of intestinal permeability.
SecondaryChange in thyroid function (TSH, free T4 and free T3)Baseline, month 4, month 8 and month 12Serum TSH, free T4 and free T3 measured by immunoassay.
SecondaryChange in micronutrient status (25-hydroxyvitamin D, ferritin and selenium)Baseline, month 4, month 8 and month 12Serum 25-hydroxyvitamin D, ferritin and selenium.
SecondaryChange in fatigue (Fatigue Severity Scale)Monthly from baseline to month 12FSS: 9 items scored 1 to 7; total score is the mean of items (range 1-7). Higher scores indicate more fatigue.
SecondaryChange in anxiety and depression (Hospital Anxiety and Depression Scale)Monthly from baseline to month 12HADS: 14 items; anxiety and depression subscales each range 0-21. Higher scores indicate worse symptoms.
SecondaryChange in health-related quality of life (WHOQOL-BREF)Monthly from baseline to month 12WHOQOL-BREF: 26 items across physical, psychological, social and environmental domains. Higher scores indicate better quality of life.
SecondaryChange in gastrointestinal symptoms (Gastrointestinal Symptom Rating Scale)Monthly from baseline to month 12GSRS: 15 items scored 1 to 7 across 5 symptom dimensions. Higher scores indicate worse symptoms.
SecondaryChange in weightMonthly from baseline to month 12Weight (kg) measured with standard anthropometric techniques.
SecondaryChange in body mass indexMonthly from baseline to month 12Weight and height, measured with standard anthropometric techniques, will be combined to report Body Mass Index in kg/m\^2 .
SecondaryChange in waist circumferenceMonthly from baseline to month 12Waist circumference (cm) measured with standard anthropometric techniques.
SecondaryDietary adherence (Nutritional Adherence Index)Monthly from baseline to month 12Percentage of days with full compliance with the assigned diet, calculated from monthly dietary records.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07879690/registered